CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

RO-0282425

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionJan 27, 2026
Entity authorityQ138143379 ↗
Source-derived summary

RO-0282425 is a melanocortin MC4 receptor agonist which was under development for the treatment of erectile dysfunction but was never marketed. Its route of administration was unspecified. The drug was under development by Roche. It reached phase 2 clinical trials by 2005 but its development was subsequently discontinued. The chemical structure of RO-0282425, and whether it is a small molecule or a peptide, do not appear to have been disclosed.

Editorial summary

Begin with the source’s own compact description: “RO-0282425” is pharmaceutical compound. The dossier treats that line as a proposition to test through RO-0282425, pharmaceutical and compound, not as a finished interpretation.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current lead gives the account dated anchors—2005—that can be checked directly. The selected authority fields contribute no independent date. For this dossier, RO-0282425, pharmaceutical and compound is the immediate research focus.
Editorial analysis

Why this record matters

The phrase “pharmaceutical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jan 27, 2026. The linked authority identifier is Q138143379. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2005.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “RO-0282425”, its source revision and the description used here.
  2. Expand the search: follow RO-0282425 primary sources, RO-0282425 archive and RO-0282425 research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “RO-0282425”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “RO-0282425” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.